Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07799544 ± PF-07799933 in BRAF-mutant advanced solid tumors (Phase 1a/b, Japan)
jRCT2031250746Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of polfurmetinib and PF-07799933 in Nonhematologic neoplasms (2 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities (DLTs) in Cycle 1, Treatment-emergent adverse events (AEs) - dose escalation and 4 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
polfurmetinibPF-07799933
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250746.